EDISON EQUITY RESEARCH - ATHERSYS

EDISON EQUITY RESEARCH: ATHERSYS - AN IMPORTANT PERIOD

 Athersys is approaching an important period in the clinical development of MultiStem, its allogeneic stem cell therapy product. Enrolment in a Phase II study for ischaemic stroke is expected to complete within a couple of months and with a 90-day efficacy endpoint, headline results should be available in Q115. Positive data could re-rate the stock and ease concerns over the failed Phase II trial in ulcerative colitis earlier this year. Also in Q414 a Phase II study in acute myocardial infarction is due to start, and regulatory approval for a pivotal Phase II/III trial in GvHD could be secured.

 Athersys is a US biotech company developing MultiStem (allogeneic, bone marrow-derived stem cells). A Phase II trial with MultiStem in ischaemic stroke is ongoing (data in Q115) and further studies in AMI (Phase II) and GvHD (Phase II/III) are planned.

To view our full report, please click here:

http://www.edisoninvestmentresearch.com/research/report/athersys10

Click here to view all of Edison Investment Research’s published reports